- Home
- MNKD
MNKD
MannKind Corporation
as 05-09-2025 9:55am EST
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | DANBURY |
| Market Cap: | 1.4B | IPO Year: | 2004 |
| Target Price: | $8.92 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.10 | EPS Growth: | 215.86 |
| 52 Week Low/High: | $4.17 - $7.63 | Next Earning Date: | 05-08-2025 |
| Revenue: | $297,595,000 | Revenue Growth: | 32.50% |
| Revenue Growth (this year): | 14.23% | Revenue Growth (next year): | 14.56% |
Latest MannKind Corporation News
MNKD Breaking Stock News: Dive into MNKD Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
MannKind's Q1 Adjusted Earnings, Revenue Increase
Zacks
a day ago
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Associated Press Finance
a day ago
MannKind: Q1 Earnings Snapshot
GlobeNewswire
a day ago
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
GuruFocus.com
2 days ago
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect
Simply Wall St.
3 days ago
US High Growth Tech Stocks To Watch In Your Portfolio
GlobeNewswire
8 days ago
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
Insider Monkey
21 days ago
Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2)
Compare MNKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNKD MannKind Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.